Gathiaka, Symon published the artcileDesign, development and evaluation of novel dual PPARδ/PPARγ agonists, HPLC of Formula: 42074-68-0, the publication is Bioorganic & Medicinal Chemistry Letters (2013), 23(3), 873-879, database is CAplus and MEDLINE.
Type 2 diabetes is at epidemic proportions and thus development of pharmaceutical therapies for improving insulin sensitivity has become of paramount importance. The objectives of the current study were to develop novel dual PPARγ/δ agonists without the deleterious side effects associated with full PPARγ agonists and several compounds were made and evaluated.. Biol. evaluation of compounds was accomplished by transcriptional promoter activity assays, quant. PCR gene anal. for known PPARγ/δ targets as well as in vitro assays for lipid accumulation and mitochondrial biogenesis verses known PPAR agonists. It was found that compound I was the most potent and selective dual PPARγ/δ agonist which did not display the deleterious side effects associated with full PPARγ agonists.
Bioorganic & Medicinal Chemistry Letters published new progress about 42074-68-0. 42074-68-0 belongs to chlorides-buliding-blocks, auxiliary class Chloride,Benzyl chloride,Benzene, name is 2-Chlorotrityl chloride, and the molecular formula is C19H14Cl2, HPLC of Formula: 42074-68-0.
Referemce:
https://en.wikipedia.org/wiki/Chloride,
Chlorides – an overview | ScienceDirect Topics